Register today for Leveraging Big Data II: What Does It Mean for Improving Product Development and Health Care?
Since the 1990s, efforts have been made to improve database development and data warehousing by pharmaceutical companies and government entities. A recent emphasis has been placed on "big data," the term for a collection of data sets so large and complex that they becomes difficult to process using traditional database management tools or data processing applications. In the world of health-related research, big data takes on many forms with varying applications, but to date, there is no universal understanding of what big data is or what it can do.
Since the 1990s, efforts have been made to improve database development and data warehousing by pharmaceutical companies and government entities. A recent emphasis has been placed on "big data," the term for a collection of data sets so large and complex that they becomes difficult to process using traditional database management tools or data processing applications. In the world of health-related research, big data takes on many forms with varying applications, but to date, there is no universal understanding of what big data is or what it can do.
Join us on February 11 for a conference, “Leveraging Big Data II: What Does It Mean for Improving Product Development and Health Care,” where health care stakeholders will explore the role of big data and its impact on innovation. Participants will include researchers from the Food and Drug Administration and other government agencies, the pharmaceutical industry and academia.
The conference will be held from 10:00 a.m. to 3:00 p.m. at the Southern Management Corporation Campus Center at the University of Maryland located at 621 West Lombard Street in Baltimore, MD.
This conference is sponsored by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), the FDA and the National Pharmaceutical Council.